Comparative

OMIA group 1513

Leukaemia, chronic myelogenous

The chain reaches the human disease chronic myeloid leukemia, which Mondo defines as: “A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.”

The chain

From the animal disease to the drugs. The page shows what each step found and where the chain stopped. It does not say whether the animal is a model of a human disease.

  1. Animal disease

    Reached

    OMIA records it in 2 species entries marked as a defect.

  2. Human disease

    Reached

    1 Mondo disease.

  3. Human gene

    Reached

    2 human genes.

  4. Target evidence

    Reached

    2 Open Targets associations, with a best score of 0.82.

  5. Drugs

    Reached

    21 ChEMBL drugs, 9 approved. At least one has been tested for this disease.

Natural-model score

How complete and how well supported the chain to each human disease is, out of 100, by stated rules. It does not say that the animal is a validated model of the human disease. How the score works.

chronic myeloid leukemia

85.8 out of 100

Part Computed from Points
Target evidence Open Targets score of 0.82 28.8 of 35
Drugs A drug has reached approved for this disease 25.0 of 25
Ortholog One to one ortholog 20.0 of 20
Both routes One route found this disease 5.0 of 10
Species 2 naturally occurring species entries marked as a defect 7.0 of 10

Species

The chain follows only the species entries that OMIA marks as a defect.

Species Scientific name OMIA entry A defect
dog Canis lupus familiaris OMIA:001513-9615 Yes
pig Sus scrofa OMIA:001513-9823 Yes

Genes

Each gene OMIA records for a species entry, and the human gene it reaches through Ensembl's orthologs.

Species Animal gene Human gene Ortholog
dog ABL1 ABL proto-oncogene 1, non-receptor tyrosine kinase NCBI Gene 491292 ABL1 Ensembl one to one
dog BCR breakpoint cluster region NCBI Gene 607482 BCR Ensembl one to one
pig ABL1 ABL proto-oncogene 1, non-receptor tyrosine kinase NCBI Gene 100524544 ABL1 Ensembl one to one
pig BCR breakpoint cluster region NCBI Gene 100157974 BCR Ensembl one to one

Human diseases

Two routes lead from an OMIA group to a Mondo human disease: OMIA's own Mondo link, and the group's OMIM numbers through Mondo's cross-references.

Mondo disease Name Found by
MONDO:0011996 chronic myeloid leukemia A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival. OMIA's OMIM numbers

Target evidence

Each Open Targets association between one of the group's human genes and one of its human diseases, with its overall score and the score for each kind of evidence.

Human gene Human disease Score Evidence Kinds of evidence
ABL1 chronic myeloid leukemia 0.82 7,216 Known drug 0.99 Literature 0.99 Affected pathway 0.97 Genetic association 0.86 Genetic literature 0.61 Somatic mutation 0.60 Animal model 0.53
BCR chronic myeloid leukemia 0.82 8,089 Known drug 0.99 Literature 0.99 Affected pathway 0.92 Genetic literature 0.61 Somatic mutation 0.61 Genetic association 0.28

Drugs

A drug acts on ABL1 and BCR and has been tested for this disease.

Drug Acts on How Latest stage Tested for this disease
Asciminib ABL1 inhibitor Approved Approved for chronic myeloid leukemia
Asciminib BCR inhibitor Approved Approved for chronic myeloid leukemia
Bosutinib ABL1 inhibitor Approved Approved for chronic myeloid leukemia
Bosutinib BCR inhibitor Approved Approved for chronic myeloid leukemia
Dasatinib Anhydrous ABL1 inhibitor Approved Approved for chronic myeloid leukemia
Dasatinib Anhydrous BCR inhibitor Approved Approved for chronic myeloid leukemia
Imatinib ABL1 inhibitor Approved Approved for chronic myeloid leukemia
Imatinib BCR inhibitor Approved Approved for chronic myeloid leukemia
Nilotinib ABL1 inhibitor Approved Approved for chronic myeloid leukemia
Nilotinib BCR inhibitor Approved Approved for chronic myeloid leukemia
Ponatinib ABL1 inhibitor Approved Approved for chronic myeloid leukemia
Ponatinib BCR inhibitor Approved Approved for chronic myeloid leukemia
Flumatinib ABL1 inhibitor Approved Phase 3 for chronic myeloid leukemia
Olverembatinib ABL1 inhibitor Phase 3 Phase 3 for chronic myeloid leukemia
Olverembatinib BCR inhibitor Phase 3 Phase 3 for chronic myeloid leukemia
Radotinib ABL1 inhibitor Phase 3 Phase 3 for chronic myeloid leukemia
Radotinib BCR inhibitor Phase 3 Phase 3 for chronic myeloid leukemia
At-9283 ABL1 inhibitor Phase 3 Phase 1/2 for chronic myeloid leukemia
Vodobatinib ABL1 inhibitor Phase 2 Phase 1/2 for chronic myeloid leukemia
Vodobatinib BCR inhibitor Phase 2 Phase 1/2 for chronic myeloid leukemia
Rebastinib ABL1 inhibitor Phase 1/2 Phase 1 for chronic myeloid leukemia
Kw-2449 ABL1 inhibitor Phase 1 Phase 1 for chronic myeloid leukemia
Xl-228 ABL1 inhibitor Phase 1 Phase 1 for chronic myeloid leukemia
Regorafenib ABL1 inhibitor Approved No
Umbralisib ABL1 inhibitor Approved No
Ruserontinib ABL1 inhibitor Phase 3 No
Saracatinib ABL1 inhibitor Phase 2/3 No
Bafetinib ABL1 inhibitor Phase 2 No
Azd-0424 ABL1 inhibitor Phase 1 No
Azm-475271 ABL1 inhibitor Unknown No

The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.